Anaplastic Astrocytoma

Despite advances in our understanding of the pathogenesis of glioblastoma, the mOS median overall survival in our real-world patient cohort did not improve over time. The findings emphasise the need for ongoing research efforts to improve outcomes in this lethal disease.

P1, N=35, Active, not recruiting, Children's Oncology Group | Trial completion date: Feb 2030 --> Dec 2027 | Trial primary completion date: Apr 2027 --> Dec 2027

P1/2, N=54, Recruiting, Northwell Health | Trial completion date: Oct 2027 --> Oct 2029 | Trial primary completion date: Oct 2026 --> Oct 2028

P1/2, N=54, Suspended, Northwell Health | Trial primary completion date: Dec 2026 --> Dec 2027

After excluding IDH-mutant grade-IV cases from the CGGA cohorts, the classification AUROCs increased to 0.906 in CGGA-325 and 0.872 in CGGA-693, with a Cox risk-score hazard ratio of 8.57 (p = 1.4 × 10-13) and log-rank p = 1.4 × 10-32 retained on the CNS5-aligned cohort. The methodological contributions introduced in this study, namely, the topology-aware hypergraph candidate pool construction, the rough set combinatorial reduct selection, the fixed-reference single-sample normalisation protocol, and the nested validation regime combining bootstrap optimism correction with cross-platform DeLong testing, are platform agnostic and directly applicable to future CNS5-aligned cohorts as such resources become publicly available, supporting the prospective re-derivation of molecularly defined glioma signatures within the integrated histopathological and molecular frameworks of contemporary neuro-oncology.

The vaccine was not effective statistically but was well tolerated and appeared to have induced WT1-specific immune responses, suggesting improved survival in WT1-specific immune responders among DIPG patients and warranting its further development.

Patients with worse OS and PFS showed a significant decline in three-month QoL metrics, especially in social/family well-being domains that preceded changes in Karnofsky Performance Status. Conclusion Advanced MRI and quantitative QoL measurements may help predict long-term survival for HGG patients but require further exploration and analysis.

The recent INDIGO trial, which demonstrated efficacy of the IDH1/2 inhibitor vorasidenib in residual grade 2 IDH-mutant glioma, has further increased the importance of preoperative imaging assessment of IDH mutation status...Third, we discuss the implications of cIMPACT-NOW Updates 8-11 for neuroradiologic diagnosis. In the WHO CNS5 era, imaging plays a central role in supporting integrated diagnosis and prioritizing appropriate molecular testing.

P1, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026

We provide empirical evidence supporting a role for histo-morphological and limited molecular testing in neuro-oncology practice in LMICs.

P1/2, N=40, Recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Not yet recruiting --> Recruiting

The presence of a hemizygous CDKN2A/B deletion occurs more frequently in astrocytomas compared to oligodendrogliomas at the time of primary diagnosis. Worse survival in patients with astrocytoma and CDKN2A/B hemizygous loss was observed, specifically in WHO grade 2, but this prognostic effect disappeared when adjusting for clinical factors.